Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › crisaborole

crisaborole

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of crisaborole

4 trials tracked of crisaborole: 3 in phase 3 or 4.

4Trials tracked
3Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 1
  1. Phase 4 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Completed
  2. Phase 4 Steroid-reducing Effects of Crisaborole Completed
  3. Phase 3 ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis Completed
  4. Phase 2 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CRS3123 shows efficacy in phase 2 trial for Clostridioides difficile infection
Infectious Disease RCT
CRS3123 shows efficacy in phase 2 trial for Clostridioides difficile infection Early trial shows CRS3123 matches vancomycin for treating C. diff infection
This phase 2 randomized trial compared CRS3123 with vancomycin in 43 adults with CDI.
A small Phase 2 trial found CRS3123 worked as well as vancomycin for curing C. diff infection in adults with their first episode or recurren…
May 1, 2026
Retrospective FAERS analysis reveals sex-specific adverse event patterns for apremilast, crisaborole, and roflumilast in chronic inflammatory diseases
Drug Pipeline Cohort
Retrospective FAERS analysis reveals sex-specific adverse event patterns for apremilast, crisaborole, and roflumilast in chronic inflammatory diseases Why Side Effects Hit Men and Women Differently
This retrospective pharmacovigilance study analyzed 127,516 apremilast reports, 7,562 crisaborole reports, and 2,142 roflumilast reports wit…
A massive new analysis reveals that common anti-inflammatory drugs cause different side effects in men and women, meaning biology is more co…
Frontiers Apr 18, 2026